Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma

NCT00124579 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00124579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2005
Completion date
June 30, 2010
Enrollment
7 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma